EU/3/02/085: Orphan designation for the treatment of glioma


Table of contents


Please note that this product was withdrawn from the Community register of designated orphan medicinal products in April 2012 on request of the sponsor.

On 5 March 2002, orphan designation (EU/3/02/085) was granted by the European Commission to Icon Clinical Research UK Ltd, United Kingdom, for carmustine (solution for intratumoural injection) for the treatment of glioma.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Intended use
Treatment of glioma
Orphan designation status
EU designation number
Date of designation
Icon Clinical Research UK Ltd
Kings Court
The Broadway
Hampshire SO23 9BE
United Kingdom
Tel. +44 (0)1962 826000
Fax +44 (0)1962 826001

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating